Transcriptional targeting of glioblastoma by diphtheria toxin-A driven by both H19 and IGF2-P4 promoters

International Journal of Clinical and Experimental Medicine

Volumn 5, Issue 2, 2012, Pages 124-135

  Amit, Doron ^a   Matouk, Imad J ^a   Lavon, Iris ^b   Birman, Tatiana ^a   Galula, Jenifer ^a   Abu Lail, Rasha ^a   Schneider, Tamar ^a   Siega, Tali ^b   Hochberg, Abraham ^a   Fellig, Yakov ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Glioblastoma; H19; H19 DTA P4 DTA; IGF2 P4; Targeted therapy

Indexed keywords

DIPHTHERIA TOXIN; DIPHTHERIA TOXIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; CANCER CELL CULTURE; CANCER GRADING; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; GENE; GENE EXPRESSION; GENE VECTOR; GLIOBLASTOMA; H19 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IGF2 P4 GENE; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84860006070     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Leibovitch MP, Nguyen VC, Gross MS, Solhonne B, Leibovitch SA and Bernheim A. The human ASM (adult skeletal muscle) gene: expression and chromosomal assignment to 11p15. Bio- chem Biophys Res Commun 1991; 180: 1241-1250.
2. Matouk I OP, Ayesh S, Sidi A, Czerniak A, de Groot N, Hochberg A The oncofetal H19 RNA in human cancer, from the bench to the patient. Cancer Therapy 2005; 3: 249-266.
3. Matouk IJ, Ohana P, Galun E, de Groot N, Ho-chberg A. The pivotal role of the H19 gene in tumor development, a new hope. In: Campbell RN(ed) Gene therapy and cancer research focus. Nova Science Publishers 2008; 241-260.
4. Tsang WP, Kwok TT. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Onco-gene 2007; 26: 4877-4881.
5. Engstrom W, Shokrai A, Otte K, Granerus M, Gessbo A, Bierke P, Madej A, Sjolund M and Ward A. Transcriptional regulation and biological significance of the insulin like growth factor II gene. Cell Prolif 1998; 31: 173-189.
6. Holthuizen PE, Cleutjens CB, Veenstra GJ, van der Lee FM, Koonen-Reemst AM and Sussen-bach JS. Differential expression of the human, mouse and rat IGF-II genes. Regul Pept 1993; 48: 77-89.
7. de Pagter-Holthuizen P, Jansen M, van der Kammen RA, van Schaik FM and Sussenbach JS. Differential expression of the human insulinlike growth factor II gene. Characterization of the IGF-II mRNAs and an mRNA encoding a putative IGF-II-associated protein. Biochim Bio-phys Acta 1988; 950: 282-295.
8. Holthuizen P, van der Lee FM, Ikejiri K, Yama-moto M and Sussenbach JS. Identification and initial characterization of a fourth leader exon and promoter of the human IGF-II gene. Bio-chim Biophys Acta 1990; 1087: 341-343.
9. Ekstrom TJ, Cui H, Li X and Ohlsson R. Promoter -specific IGF2 imprinting status and its plasticity during human liver development. Development 1995; 121: 309-316.
10. Giannoukakis N, Deal C, Paquette J, Goodyer CG and Polychronakos C. Parental genomic imprinting of the human IGF2 gene. Nat Genet 1993; 4: 98-101.
11. Ohlsson R, Franklin G. Normal development and neoplasia: the imprinting connection. Int J Dev Biol 1995; 39: 869-876.
12. Morison IM, Reeve AE. Insulin-like growth factor 2 and overgrowth: molecular biology and clinical implications. Mol Med Today 1998; 4: 110-115.
13. Wu HK, Squire JA, Catzavelos CG and Weksberg R. Relaxation of imprinting of human insulinlike growth factor II gene, IGF2, in sporadic breast carcinomas. Biochem Biophys Res Com-mun 1997; 235: 123-129.
14. Muller S, Zirkel D, Westphal M and Zumkeller W. Genomic imprinting of IGF2 and H19 in human meningiomas. Eur J Cancer 2000; 36: 651-655.
15. Albrecht S, Waha A, Koch A, Kraus JA, Goodyer CG and Pietsch T. Variable imprinting of H19 and IGF2 in fetal cerebellum and medulloblas-toma. J Neuropathol Exp Neurol 1996; 55: 1270-1276.
16. Corcoran RB, Bachar Raveh T, Barakat MT, Lee EY and Scott MP. Insulin-like growth factor 2 is required for progression to advanced medul-loblastoma in patched1 heterozygous mice. Cancer Res 2008; 68: 8788-8795.
17. Hartmann W, Koch A, Brune H, Waha A, Schuller U, Dani I, Denkhaus D, Langmann W, Bode U, Wiestler OD, Schilling K and Pietsch T. Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cells. Am J Pathol 2005; 166: 1153-1162.
18. Uyeno S, Aoki Y, Nata M, Sagisaka K, Kayama T, Yoshimoto T and Ono T. IGF2 but not H19 shows loss of imprinting in human glioma. Cancer Res 1996; 56: 5356-5359.
19. Antoniades HN, Galanopoulos T, Neville-Golden J and Maxwell M. Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer 1992; 50: 215-222.
20. Brockmann MA, Ulbricht U, Gruner K, Fillbrandt R, Westphal M and Lamszus K. Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 2003; 52: 1391-1399; discussion 1399.
21. Morford LA, Boghaert ER, Brooks WH and Rosz-man TL. Insulin-like growth factors (IGF) enhance three-dimensional (3D) growth of human glioblastomas. Cancer Lett 1997; 115: 81-90.
22. Soroceanu L, Kharbanda S, Chen R, Soriano RH, Aldape K, Misra A, Zha J, Forrest WF, Nigro JM, Modrusan Z, Feuerstein BG and Phillips HS. Identification of IGF2 signaling through phos-phoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci USA 2007; 104: 3466-3471.
23. Rorive S, Berton A, D'Haene N, Takacs CN, De-beir O, Decaestecker C and Salmon I. Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motil-ity in astrocytomas. Glia 2008; 56: 1679-1690.
24. Matouk IJ, Mezan S, Mizrahi A, Ohana P, Abu-Lail R, Fellig Y, Degroot N, Galun E and Ho-chberg A. The oncofetal H19 RNA connection: hypoxia, p53 and cancer. Biochim Biophys Acta 2010; 1803: 443-451.
25. Lewis BC, Klimstra DS, Socci ND, Xu S, Koutcher JA and Varmus HE. The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol Cell Biol 2005; 25: 1228-1237.
26. Park IY, Sohn BH, Choo JH, Joe CO, Seong JK, Lee YI and Chung JH. Deregulation of DNA me-thyltransferases and loss of parental methyla-tion at the insulin-like growth factor II (Igf2)/ H19 loci in p53 knockout mice prior to tumor development. J Cell Biochem 2005; 94: 585-596.
27. Gariboldi MB, Ravizza R and Monti E. The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol 2010; 80: 455-462.
28. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier CP. CD133(+) and CD133 (-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-4015.
29. Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A and Galun E. The H19 non-coding RNA is essential for human tumor growth. PLoS ONE 2007; 2: e845.
30. Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR Jr. and Gillespie GY. CD133 is a marker of bioenergetic stress in human glioma. PLoS One 2008; 3: e3655.
31. von Deimling A BP, Nakazato Y, et al. Diffuse astrocytomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). World Health Organization Classification of Tumours. Pathology and genetics of tumours of the nervous system. Lyon, IARC 2007; pp 25-29.
32. Kleihues P BP, Aldape KD, et al. Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). World Health Organization Classification of Tumours. Pathology and genetics of tumours of the nervous system. Lyon, IARC 2007; pp 33-49.
33. Ohana P, Bibi O, Matouk I, Levy C, Birman T, Ariel I, Schneider T, Ayesh S, Giladi H, Laster M, de Groot N and Hochberg A. Use of H19 regulatory sequences for targeted gene therapy in cancer. Int J Cancer 2002; 98: 645-650.
34. Ayesh B, Matouk I, Ohana P, Sughayer MA, Birman T, Ayesh S, Schneider T, de Groot N and Hochberg A. Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences. Mol Ther 2003; 7: 535-541.
35. Amit D, Hochberg A. Development of targeted therapy for bladder cancer mediated by a dou-ble promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. J Transl Med 2010; 8: 134.
36. Mizrahi A, Czerniak A, Levy T, Amiur S, Gallula J, Matouk I, Abu-lail R, Sorin V, Birman T, de Groot N, Hochberg A and Ohana P. Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences. J Transl Med 2009; 7: 69.
37. Mizrahi A, Hochberg A, Amiur S, Gallula J, Ma-touk I, Birman T, Levy T, Ladimir S and Ohana P. Targeting diphtheria toxin and TNF alpha expression in ovarian tumors using the H19 regulatory sequences. Int J Clin Exp Med 2009; 3: 270-282.
38. Ohana P, Schachter P, Ayesh B, Mizrahi A, Bir-man T, Schneider T, Matouk I, Ayesh S, Kuppen PJ, de Groot N, Czerniak A and Hochberg A. Regulatory sequences of H19 and IGF2 genes in DNA-based therapy of colorectal rat liver metastases. J Gene Med 2005; 7: 366-374.
39. Scaiewicz V, Sorin V, Fellig Y, Birman T, Mizrahi A, Galula J, Abu-Lail R, Shneider T, Ohana P, Buscail L, Hochberg A and Czerniak A. Use of H19 Gene Regulatory Sequences in DNA-Based Therapy for Pancreatic Cancer. J Oncol 2010; 2010: 178-174.
40. Sidi AA, Ohana P, Benjamin S, Shalev M, Ransom JH, Lamm D, Hochberg A and Leibovitch I. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. J Urol 2008; 180: 2379-2383.
41. Mizrahi A, Czerniak A, Ohana P, Amiur S, Gallula J, Matouk I, Abu-Lail R, Birman T, Hochberg A and Levy T. Treatment of ovarian cancer ascites by intra-peritoneal injection of diphtheria toxin A chain-H19 vector: a case report. J Med Case Reports 2010; 4: 228.
42. Ariel I, Miao HQ, Ji XR, Schneider T, Roll D, de Groot N, Hochberg A and Ayesh S. Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma. Mol Pathol 1998; 51: 21-25.
43. Ariel I, Sughayer M, Fellig Y, Pizov G, Ayesh S, Podeh D, Libdeh BA, Levy C, Birman T, Tykocin-ski ML, de Groot N and Hochberg A. The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. Mol Pathol 2000; 53: 320-323.
44. Fellig Y, Ariel I, Ohana P, Schachter P, Sinel-nikov I, Birman T, Ayesh S, Schneider T, de Groot N, Czerniak A and Hochberg A. H19 expression in hepatic metastases from a range of human carcinomas. J Clin Pathol 2005; 58: 1064-1068.
45. Ayesh S, Matouk I, Schneider T, Ohana P, Las-ter M, Al-Sharef W, De-Groot N and Hochberg A. Possible physiological role of H19 RNA. Mol Carcinog 2002; 35: 63-74.
46. Fellig Y AD, Matouk IJ, Kopolovic J, Erdmann VA, Hochberg A. The non-coding oncofetal H19 gene in brain tumors. In Erdmann VA, Reifen-berger G, Barciszewski J (eds). Therapeutic ribonucleic acids in brain tumors. Springer Ver-lag Berlin Heidelberg 2009; pp 471-484.
47. Cooper MJ. Noninfectious gene transfer and expression systems for cancer gene therapy. Semin Oncol 1996; 23: 172-187.
48. Kouraklis G. Gene therapy for cancer: from the laboratory to the patient. Dig Dis Sci 2000; 45: 1045-1052.
49. Kawase A, Nomura T, Yasuda K, Kobayashi N, Hashida M and Takakura Y. Disposition and gene expression characteristics in solid tumors and skeletal muscle after direct injection of naked plasmid DNA in mice. J Pharm Sci 2003; 92: 1295-1304.
50. Maxwell IH, Glode LM and Maxwell F. Expression of diphtheria toxin A-chain in mature B-cells: a potential approach to therapy of B-lymphoid malignancy. Leuk Lymphoma 1992; 7: 457-462.
51. Engebraaten O, Hjortland GO, Juell S, Hirschberg H and Fodstad O. Intratumoral im-munotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer 2002; 97: 846-852.
52. Laske DW, Youle RJ and Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997; 3: 1362-1368.
53. Liu TF, Hall PD, Cohen KA, Willingham MC, Cai J, Thorburn A and Frankel AE. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res 2005; 11: 329-334.
54. Liu TF, Willingham MC, Tatter SB, Cohen KA, Lowe AC, Thorburn A and Frankel AE. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Biocon-jug Chem 2003; 14: 1107-1114.
55. Martell LA, Agrawal A, Ross DA and Muraszko KM. Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res 1993; 53: 1348-1353.
56. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003; 65: 3-13.
57. Ferguson SD, Foster K and Yamini B. Convection-enhanced delivery for treatment of brain tumors. Expert Rev Anticancer Ther 2007; 7: S79-s85.
58. Hall WA, Sherr GT. Convection-enhanced delivery of targeted toxins for malignant glioma. Expert Opin Drug Deliv 2006; 3: 371-377.
59. Rainov NG, Gorbatyuk K and Heidecke V. Clinical trials with intracerebral convection-enhanced delivery of targeted toxins in malignant glioma. Rev Recent Clin Trials 2008; 3: 2-9.